Evaluation of the TRIP13 level in breast cancer and insights into potential molecular pathways

Abstract Background: TRIP13 is a member belonging to a large AAA+ ATPases protein super family. Emerging evidences had shown that TRIP13 may serve as an oncogene However, the function of TRIP13 in BC has not yet been elucidated. Methods: By utilizing the multiple database across BC, we presented the expression of TRIP13 in BC tissue and normal control. We then verified the expression of TRIP13 in patients with BC by immunohistochemical (IHC) staining. Kaplan-Meier plots were used to perform the survival analysis. Further, gene ontology (GO) analysis, gene set enrichment analysis (GSEA), and PPI (protein-protein interaction) network were performed to explore the biological function and potential regular pathway of TRIP13 in BC. Results: The multiple database and immunohistochemical (IHC) showed that higher TRIP13 expression in BC tissue compared to normal tissue. TRIP13 was highly exprssed in lung metastasis lesion compared with primary tumor in our BALB/C mice 4T1 BC models. Kaplan-Meier plots also revealed that high TRIP13 expression correlated to poor survival in patients with BC. Moreover, GSEA analysis revealed that TRIP13 was primarily enriched in the processes of cell division and proliferation. Finally 10 hub genes with a high score of connectivity were filtered from the PPI network, including MAD2L1, CDC20, CDC5L, CDK1, CCNA2, BUB1B, RAD51, SPO11, KIF11 and AURKB. Conclusion: High TRIP13 expression predicted poor prognosis and contributed tumor growth and metastasis in the BC. Thus, ARL3 may be a prognostic marker and therapeutic target for glioma. TRIP13 may be a favorable biomarker and effective therapeutic target for BC. Keywords: TRIP13; breast cancer; metastasis; bioinformatic analysis, prognosis